Plasma TGF-β1 in pediatric cystic fibrosis: Potential biomarker of lung disease and response to therapy

Pediatric Pulmonology

Volumn 46, Issue 7, 2011, Pages 688-695

  Harris, William T ^a   Muhlebach, Marianne S ^b   Oster, Robert A ^c   Knowles, Michael R ^b   Clancy, J P ^a   Noah, Terry L ^b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

Airway remodeling; Blood; Bronchoalveolar lavage fluid; Genetic modifiers; Lung disease; Serum

Indexed keywords

ANTIBIOTIC AGENT; TRANSFORMING GROWTH FACTOR BETA1; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CHILD; CHILD HOSPITALIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMAN; INFANT; LUNG DISEASE; LUNG FUNCTION; LUNG LAVAGE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PARAMETER; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMANS; INFANT; MALE; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY FUNCTION TESTS; TRANSFORMING GROWTH FACTOR BETA1; YOUNG ADULT;

EID: 79959849105     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21430     Document Type: Article

References (33)

1. Arkwright PD, Laurie S, Super M, Pravica V, Schwarz MJ, Webb AK. Hutchinson IV. TGF-beta(1) genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax 2000;55:459-462.
2. Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, Darrah RJ, Dorfman R, Sandford AJ, Corey M, Zielenski J, Durie P, Goddard K, Yankaskas JR, Wright FA, MRK. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005;353:1443-1453. (Pubitemid 41400918)
3. Collaco JM, Vanscoy L, Bremer L, McDougal K, Blackman SM, Bowers A, Naughton K, Jennings J, Ellen J, Cutting GR. Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease. JAMA 2008;299:417-424. (Pubitemid 351185950)
4. Corvol HBP, Boelle PY, Brouard J, Knauer N, Chadelat K, Henrion-Caude A, Flamant C, Muselet-Charlier C, Boule M, Fauroux B, Vallet C, Feingold J, Ratjen F, Grasemann H, Clement A. Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis. Pediatr Pulmonol 2008;43:1224-1232.
5. Collaco JM, Cutting GR. Update on gene modifiers in cystic fibrosis. Curr Opin Pulm Med 2008;14:559-566.
6. Shi W, Xu J, Warburton D. Development, repair and fibrosis: what is common and why it matters. Respirology 2009;14:656-665.
7. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-β regulation of immune responses. Annu Rev Immunol 2006;24:99-146.
8. Bartram U, Speer CP. The role of transforming growth factor β in lung development and disease. Chest 2004;125:754-765. (Pubitemid 38223659)
9. Magnan A, Frachon I, Rain B, Peuchmaur M, Monti G, Lenot B, Fattal M, Simonneau G, Galanaud P, Emilie D. Transforming growth factor β in normal human lung: preferential location in bronchial epithelial cells. Thorax 1994;49:789-792. (Pubitemid 24250237)
10. Kropf J, Schurek JO, Wollner A, Gressner AM. Immunological measurement of transforming growth factor-β1 (TGF-β1) in blood; assay development and comparison. Clin Chem 1997;43:1965-1974. (Pubitemid 27452289)
11. Reinhold D, Bank U, Buhling F, Junker U, Kekow J, Schleicher E, Ansorge S. A detailed protocol for the measurement of TGF-beta1 in human blood samples. J Immunol Methods 1997;209:203-206. (Pubitemid 28055709)
12. Wakefield L, Letterio J, Chen T, Danielpour D, Allison R, Pai L, Denicoff A, Noone M, Cowan K, O'Shaughnessy J, Sporn M. Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Can Res 1995;1:129-136.
13. O'Brien P, Ramanathan R, Yingling J, Baselga J, Rothenberg M, Carducci M, Daly T, Adcock D, Lahn M. Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases. Biologics 2008;2:563-569.
14. El-Gamel A, Awad M, Hasleton P, Yonan N, Hutchinson J, Campbell C, Rahman A, Deiraniya A, Sinnott P, Hutchinson I. Transforming growth factor-beta (TGF-beta1) genotype and lung allograft fibrosis. J Heart Lung Transplant 1999;18: 517-523. (Pubitemid 29291657)
15. Awad M, El-Gamel APH, Turner D, Sinnott P, Hutchinson I. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998;66:1014-1020. (Pubitemid 28513380)
16. Brazova JSK, Vavrova V, Bartosova J, Macek M, Jr., Lauschman H, Sediva A. Polymorphisms of TGF-beta1 in cystic fibrosis patients. Clin Immunol 2006;121:350-357. (Pubitemid 44738719)
17. Muhlebach M, Stewart P, Leigh M, Noah T. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999;160:186-191. (Pubitemid 29326086)
18. Muhlebach MS, Miller MB, Moore C, Wedd JP, Drake AF, Leigh MW. Are lower airway or throat cultures predictive of sinus bacteriology in cystic fibrosis? Pediatr Pulmonol 2006;41: 445-451.
19. Harris WT, Muhlebach MS, Oster RA, Knowles MR, Noah TL. Transforming growth factor β1 in bronchoalviolar lavage fluid from children with cystic fibrosis. Pediatr Pulmonol 2009;44: 1057-1064.
20. Miller MB, Gilligan PH. Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J Clin Microbiol 2003;41:4009-4015. (Pubitemid 37099657)
21. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, ATS/ERS Task Force. Standardization of spirometry. Eur Resp J 2005;26:319-338.
22. Hankinson JL, Odencrantz J, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Resp Care Crit Med 1999;159:179-187. (Pubitemid 29036522)
23. Eigen H, Bieler H, Grant D, Christoph K, Terrill D, Heilman DK, Ambrosius WT, Tepper RS. Spirometric pulmonary function in healthy preschool children. Am J Resp Crit Care Med 2001;163: 619-623. (Pubitemid 32230819)
24. Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson RL, Goss CH, Ramsey B. Disease-specific reference equations for lung function in patients with cystic fibrosis. Am J Respir Crit Care Med 2005;172:885-891. (Pubitemid 41369073)
25. Rosner BA. Fundamentals of biostatistics. 6th edition. Belmont, CA: Duxbury; 2006. pp. 325-331.
26. Zimmermann R, Koenig J, Zingsem J, Weisbach V, Strasser E, Ringwald J, Eckstein R. Effect of specimen anticoagulation on the measurement of circulating platelet-derived growth factors. Clin Chem 2005;51:2365-2368. (Pubitemid 41692585)
27. Konstan M, Hilliard K, Norvell T, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation.Am J Respir Crit Care Med 1994;150:448-454.
28. Paul K, Rietschel E, Ballman M, Griese M, Worlitzsch D, Shute J, Chen C, Schink T, Doring G, Van Koningsbruggen S, Wahn U, Ratjen F. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004;169:719-725. (Pubitemid 38338924)
29. Hilliard TN, Regamey N, Shute JK, Nicholson AG, Alton EW, Bush A, Davies JC. Airway remodelling in children with cystic fibrosis. Thorax 2007;62:1074-1080. (Pubitemid 350206200)
30. Dorfman R, Sandford A, Taylor C, Huang B, Frangolias D, Wang Y, Sang R, Pereira L, Sun L, Berthiaume Y, Tsui LC, Pare PD, Durie P, Corey M, Zielenski J. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest 2008;118:1040-1049. (Pubitemid 351364611)
31. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
32. Mayer-Hamblett N, Ramsey BW, Kronmal RA. Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc 2007;4:370-377. (Pubitemid 47330874)
33. Sheppard D. Transforming growth factor beta: a central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc 2006;3:413-417. (Pubitemid 44033355)